Geralyn Ritter

Recognition of the business case for ESG in pharma is soaring.

Nevertheless, it’s time to reassess how to leverage for greatest impact.

Drug access leads list of issues raised by pharma shareholders.

There is room to improve what good looks like across the industry.

Examining efforts to boost women representation on company boards.

The validity of ESG-driven investment and reporting in healthcare.

How principles of both can help companies navigate future storms.

Instead, incorporate ESG into your long-term business planning.